Mon panier

Plasma Kallikrein/KLKB1

Plasma Kallikrein/KLKB1 Informations sur la molécule

Nom anglaisPlasma kallikreinNombre de médicaments commercialisés4
Nombre de médicaments cliniques13Alias de la cibleEC:3.4.21.34,EC 3.4.21,Fletcher factor,Plasma prekallikrein,KLKB1,Kallikrein B1,Kallikrein B, Plasma (Fletcher Factor) 1,Kininogenin,KLK3,PKK,Plasma Kallikrein,EC 3.4.21.34,PKKD,PPK,PKal,pKAL
Phase de R&D la plus avancéeApproved
Nom anglaisPlasma kallikrein
Alias de la cibleEC:3.4.21.34,EC 3.4.21,Fletcher factor,Plasma prekallikrein,KLKB1,Kallikrein B1,Kallikrein B, Plasma (Fletcher Factor) 1,Kininogenin,KLK3,PKK,Plasma Kallikrein,EC 3.4.21.34,PKKD,PPK,PKal,pKAL
Nombre de médicaments commercialisés4
Nombre de médicaments cliniques13
Phase de R&D la plus avancéeApproved

Plasma Kallikrein/KLKB1 Liste de produits

  • Attribut

    Protein (3)

  • Bibliothèque de produits

    En ligne (3)

  • Espèces

    Mouse (1)Human (1)Cynomolgus (1)

  • Étiquette

    His Tag (3)

  • Marqueur

    Unconjugated (3)

Plasma Kallikrein/KLKB1Contexte de la molécule

Human Plasma Kallikrein, a serine protease, is synthesized in the liver and circulates in the plasma by binding to high molecular weight (HMW) kininogen or as a free zymogen. The enzyme cleaves Lys-Arg and Arg-Ser bonds. It activates, in a reciprocal reaction, factor XII after its binding to a negatively charged surface. It also releases bradykinin from HMW kininogen and may also play a role in the renin-angiotensin system by converting prorenin into renin.

Plasma Kallikrein/KLKB1Alias de la molécule

Fletcher factor,kallikrein B, plasma (Fletcher factor) 1,kininogenin,KLK3 plasma kallikrein,KLKB1,plasma kallikrein heavy chain,plasma kallikrein light chain,Plasma Kallikrein,Plasma Prekallikrein,PPK,KLKB1

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
NavenibartQLS-215; STAR-0215Phase 3 ClinicalQuellis Biosciences IncAngioedemas, Hereditary
Details
ADX-324ADX-324; ADX324Phase 3 ClinicalADARx Pharmaceuticals IncAngioedemas, Hereditary
Details
Lonvoguran ZiclumeranNTLA-2002Phase 3 ClinicalIntellia Therapeutics IncAngioedemas, Hereditary
Details
THR-149TG-758; THR-149Phase 2 ClinicalBicycle Therapeutics, Thrombogenics IncDiabetes Mellitus; Diabetic macular oedema; Diabetic Retinopathy
Details
BW-20805BW-20805; BW20805Phase 2 ClinicalHangzhou Bolin Pharmaceutical Technology Co LtdAngioedemas, Hereditary
Details
MDPK-67bDM-107; MDPK-67; MDPK-67b; MDKP 67b; RIK-7Phase 1 ClinicalMed DiscoveryProstatic Neoplasms
Details
MSB-03MSB-03Phase 1 ClinicalMatriSys Bioscience IncRosacea
Details
AvoralstatBCX-V; BCX-4161Phase 1 ClinicalBiocryst Pharmaceuticals IncAngioedemas, Hereditary; Diabetic macular oedema
Details
ADX-324(Tenacia)ADX324; ADX-324Phase 1 ClinicalYuanyi Biotechnology (Shanghai) Co., Ltd.Angioedemas, Hereditary
Details
ZKLJ-02Phase 1 ClinicalKunming Longjin Pharmaceutical Co LtdCardiovascular Diseases; Ischemic Stroke; Nervous System Diseases; Stroke
Details
ATN-249ATN-249Phase 1 ClinicalAttune PharmaceuticalsAngioedemas, Hereditary
Details
BI-ZClinicalBoehringer Ingelheim Pharma Gmbh & Co KgWet Macular Degeneration
Details
mRNA encoded Cas9 targeting human KLKB 1 gene therapy (Pharma Gateway)ClinicalPharma Gateway ABAngioedemas, Hereditary
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
Lanadelumab2372V1TKXK (UNII code); X124-G01; SHP-643; DX-2930; TAK-743ApprovedDyax PharmaTakhzyro, 达泽优United StatesAngioedemas, HereditaryDyax Corp2018-08-23Angioedema; Angioedemas, Hereditary; Coronavirus Disease 2019 (COVID-19); Hereditary Autoinflammatory Diseases; Lung Injury
Details
BerotralstatBCX-7353ApprovedBiocryst Pharmaceuticals IncORLADEYOUnited StatesAngioedemas, HereditaryBiocryst Pharmaceuticals Inc2020-12-03Angioedemas, Hereditary
Details
EcallantideDX-88; EPI-KAL2; FOV-2302; CB-500929ApprovedDyax PharmaKalbitorUnited StatesAngioedemaDyax Corp2009-12-01Angioedema; Angioedemas, Hereditary; Blood Loss, Surgical; Hemorrhage; Hereditary Angioedema Types I and II; Macular Edema; Retinal Vein Occlusion
Details
SebetralstatKVD-900ApprovedVantia Therapeutics Ltd.EkterlyUnited StatesAngioedemas, HereditaryKalvista Pharmaceuticals Ltd, Kalvista Pharmaceuticals Inc2025-07-03Angioedemas, Hereditary
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments commercialisés
  • Informations sur les médicaments cliniques